THE COMBINATION OF IBRUTINIB AND VENETOCLAX (ABT-199) RAPIDLY ACHIEVES COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PRELIMINARY RESULTS OF THE PHASE II AIM STUDY

被引：0
|
作者：
Tam, C. [1 ]
Roberts, A. [2 ]
Anderson, M. A. [2 ]
Dawson, S. J. [1 ]
Hicks, R. [1 ]
Pott, C. [3 ]
Westerman, D. [1 ]
Burke, G. [1 ]
Kamel, S. [4 ]
Dreyling, M. [5 ]
Dawson, M. [1 ]
Seymour, J. [1 ]
机构：
[1] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia
[2] Melbourne Hlth, Parkville, Vic, Australia
[3] Univ Hosp Schleswig Holstein, Kiel, Germany
[4] St Vincents Hosp, Melbourne, Vic, Australia
[5] Univ Munich, Munich, Germany
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P316
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [31] Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS PhaseI Clinical Trial
    Le Gouill, Steven
    Morschhauser, Franck
    Bouabdallah, Krimo
    Cartron, Guillaume
    Casasnovas, Rene-Olivier
    Milpied, Noel-Jean
    Gastinne, Thomas
    Davies, Andrew John
    Herbaux, Charles
    Chiron, David
    Callanan, Mary
    Rule, Simon
    BLOOD, 2018, 132
  • [32] OAsis: An international phase I trial of obinutuzumab, venetoclax plus ibrutinib in relapsed/refractory mantle cell lymphoma.
    Le Gouill, Steven
    Davies, Andrew
    Bouabdallah, Kamal
    Chiron, David
    Rule, Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma
    Kim, Austin I.
    Armand, Philippe
    Redd, Robert A.
    Forsyth, Megan
    Branch, Paul
    Pazienza, Samantha
    Brennan, Lisa
    Patterson, Victoria
    Waisgerber, Susan M.
    Merryman, Reid W.
    Fisher, David C.
    Ryan, Christine E.
    Ahn, Inhye E.
    Crombie, Jennifer L.
    Odejide, Oreofe O.
    LaCasce, Ann
    Jacobson, Caron A.
    Jacobsen, Eric
    Parry, Erin M.
    Davids, Matthew S.
    Brown, Jennifer R.
    Freedman, Arnold S.
    Riedell, Peter A.
    Murakami, Mark Alan
    BLOOD, 2023, 142
  • [34] Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study
    Phillips, Tycel Jovelle
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Crump, Michael
    Trneny, Marek
    Bartlett, Nancy L.
    Zaucha, Jan
    Wrobel, Tomasz
    Offner, Fritz
    Humphrey, Kathryn
    Relf, James
    de L'Etang, Audrey Filezac
    Carlile, David J.
    Byrne, Ben
    Qayum, Naseer
    Lundberg, Linda
    Dickinson, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (03)
  • [35] Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma
    Wallace, Danielle S.
    Rowland, Chris
    Hill, Brian T.
    Baran, Andrea M.
    Casulo, Carla
    Reagan, Patrick M.
    Winter, Allison
    Karmali, Reem
    Winter, Jane N.
    Gordon, Leo I.
    Bui, Andrew
    Sportelli, Peter
    Miskin, Hari P.
    Weiss, Michael S.
    Friedberg, Jonathan W.
    Ma, Shuo
    Barr, Paul M.
    LEUKEMIA & LYMPHOMA, 2023,
  • [36] Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study
    Handunnetti, Sasanka M.
    Khot, Amit
    Anderson, Mary Ann
    Blombery, Piers
    Burbury, Kate
    Ritchie, David
    Hicks, Rodney J.
    Birbirsa, Besiat
    Bressel, Mathias
    Di Iulio, Juliana
    Westerman, David Alan
    Lade, Stephen
    Roberts, Andrew W.
    Seymour, John F.
    Tam, Constantine S.
    BLOOD, 2019, 134
  • [37] Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis
    Dong-Yeop Shin
    Seok Jin Kim
    Dok Hyun Yoon
    Yong Park
    Jee Hyun Kong
    Jeong-A Kim
    Byung-Su Kim
    Hyo Jung Kim
    Jong-Ho Won
    Sung-Kyu Park
    Won Seog Kim
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 865 - 873
  • [38] Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis
    Shin, Dong-Yeop
    Kim, Seok Jin
    Yoon, Dok Hyun
    Park, Yong
    Kong, Jee Hyun
    Kim, Jeong-A
    Kim, Byung-Su
    Kim, Hyo Jung
    Won, Jong-Ho
    Park, Sung-Kyu
    Kim, Won Seog
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (04) : 865 - 873
  • [39] Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): Primary endpoint assessment of the phase 2 AIM study.
    Tam, Constantine Si Lun
    Roberts, Andrew Warwick
    Anderson, Mary Ann
    Dawson, Sarah-Jane
    Hicks, Rodney J.
    Burbury, Kate
    Turner, Gillian
    Di Iulio, Juliana
    Bressel, Mathias
    Westerman, David A.
    Agarwal, Rishu
    Pott, Christiane
    Dreyling, Martin H.
    Dawson, Mark A.
    Seymour, John Francis
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study
    Morschhauser, Franck
    Bouabdallah, Kamal
    Stilgenbauer, Stephan
    Thieblemont, Catherine
    de Guibert, Sophie
    Zettl, Florian
    Gelbert, Lawrence M.
    Turner, P. Kellie
    Kambhampati, Siva Rama Prasad
    Li, Li
    Li, Lily Q.
    Buchanan, Sean
    Barriga, Susana
    Bear, Melissa M.
    Wilhelm, Martin
    Hess, Georg
    HAEMATOLOGICA, 2021, 106 (03) : 859 - 862
12345